Cite

HARVARD Citation

    Stinchcombe, T. et al. (n.d.). 1444PA randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Annals of oncology. p. . [Online]. 
  
Back to record